COLL - NASDAQ

Collegium Pharmaceutical, Inc.

COLL·NASDAQ

$31.06

+1.9%

HealthcareDrug Manufacturers - Specialty & Generic

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.01B

EPS1.9800

P/E Ratio15.69

Earnings Date08/06/2026

1.66B

Assets

3Y+41.0%

5Y+157.0%

10Y+923.0%

1.36B

Total Liabilities

-6%

3Y+38.0%

5Y+196.0%

10Y+4899.0%

301.68M

Total Equity

32%

3Y+55.0%

5Y+62.0%

10Y+124.0%

Collegium Pharmaceutical, Inc. Funding & Solvency Profile

COLL · NASDAQ

Current Assets

Cash & Cash Equivalents251.10M

Net Receivables211.33M

Inventory40.91M

Other Current Assets3.24M

Total Current Assets691 M

Non-Current Assets

Property, Plant & Equipment16.20M

Goodwill & Intangible Assets815.43M

Long-Term Investments1.06M

Other Non-Current Assets20.19M

Total Non-Current Assets37 M

Total Assets

1.66B

Financial Health Analysis

Current Ratio

1.57x

Strong liquidity. The company has adequate resources to meet short-term liabilities.

Debt-to-Equity Ratio

4.49x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

251 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

42% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Collegium Pharmaceutical, Inc. Balance Sheet

COLL • NASDAQ

Collegium Pharmaceutical, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	251.1M	70.6M	238.9M	173.7M	186.4M	174.1M	170M	146.6M	118.7M	153.2M	95.7M	1.6M	7.6M
Short-Term Investments	155.4M	92.2M	71.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	406.5M	162.8M	310.5M	173.7M	186.4M	174.1M	170M	146.6M	118.7M	153.2M	95.7M	1.6M	7.6M
Net Receivables	211.3M	228.5M	179.5M	183.1M	105.8M	83.3M	73M	77.9M	10M	2.1M	0.0	0.0	0.0
Accounts Receivables	211.3M	228.5M	179.5M	183.1M	105.8M	83.3M	73M	77.9M	10M	2.1M	0.0	0.0	0.0
Inventory	40.9M	35.6M	32.3M	46.5M	17.4M	15.6M	9.6M	7.8M	1.8M	1.3M	0.0	0.0	0.0
Prepaids	29.4M	27.7M	15.1M	16.6M	5.9M	4.8M	3M	4.1M	2.5M	1.6M	628K	41K	710K
Other Current Assets	3.2M	27.7M	93K	57K	27K	60K	141K	1M	456K	304K	558K	2.8M	0.0
Total Current Assets	691.4M	482.3M	537.6M	420M	315.5M	277.9M	255.7M	237.5M	133.5M	158.6M	96.9M	4.5M	8.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	16.2M	20.2M	22M	26.4M	27.1M	27.4M	20.9M	9.3M	1.8M	1M	738K	514K	693K
Goodwill	145.9M	162.3M	133.9M	133.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	669.5M	891.4M	421.7M	567.5M	268.7M	335.9M	29.5M	44.3M	0.0	2.1M	0.0	0.0	0.0
Goodwill & Intangible Assets	815.4M	1.1B	555.6M	701.2M	268.7M	335.9M	29.5M	44.3M	0.0	2.1M	0.0	0.0	0.0
Long-Term Investments	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	97K	97K	97K	0.0	0.0
Tax Assets	112.5M	98M	26.3M	24M	78M	0.0	0.0	0.0	0.0	-97K	0.0	0.0	0.0
Other Non-Current Assets	20.2M	9.4M	1.9M	2.6M	2.6M	2.7M	178K	204K	161K	301K	0.0	80K	80K
Total Non-Current Assets	965.4M	1.2B	605.7M	754.1M	376.5M	366M	50.6M	53.7M	2.1M	3.4M	835K	594K	773K
Total Assets	1.7B	1.7B	1.1B	1.2B	692.1M	643.8M	306.3M	291.2M	135.6M	162M	97.7M	5.1M	9M
LIABILITIES
CURRENT LIABILITIES
Total Payables	14M	48.1M	10.8M	7.8M	7.4M	11.8M	6.2M	12.2M	5.7M	9.1M	3.5M	2.2M	1.2M
Accounts Payable	10.7M	3.9M	8.7M	3.5M	4.2M	10M	6.2M	12.2M	5.7M	9.1M	3.5M	2.2M	1.2M
Other Payables	3.3M	44.1M	2.1M	4.4M	3.2M	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	16.3M	388M	7.9M	260.8M	222.2M	178M	185.3M	7.6M	6.1M	4.6M	1.6M	635K	449K
Short Term Debt	30.4M	64.6M	183.3M	162.5M	48.4M	47.5M	3.8M	1.6M	1.5M	2.7M	2.7M	6.2M	333K
Capital Lease Obligations (Current)	0.0	1.3M	988K	1.1M	814K	730K	656K	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	15.2M	7.1M	4.4M	3.2M	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	667K	0.0	988K	0.0	0.0	0.0	0.0	0.0	0.0	4.9M	-9.5M	0.0	0.0
Other Current Liabilities	378.7M	7.6M	253.9M	1.5M	851K	1.4M	5.7M	167.7M	18.2M	4.3M	661K	1.4M	619K
Total Current Liabilities	440M	509.5M	457.9M	433.7M	279.6M	239.5M	201.8M	187.5M	31.5M	22.9M	5.8M	10.4M	2.6M
NON-CURRENT LIABILITIES
Long Term Debt	906M	787.9M	483.8M	538.5M	201.6M	209.6M	7.7M	9.9M	0.0	1.5M	4.1M	6.8M	640K
Deferred Revenue (Non-Current)	9.1M	10M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	-4.1M	121.8M	0.0	0.0	0.0	0.0	0.0	676K	0.0	0.0	0.0	0.0	59K
Total Non-Current Liabilities	915.1M	925.2M	490M	545.6M	209.6M	218.4M	17.1M	12.2M	7.2M	4.2M	6.9M	6.9M	834K
Other Liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-7.2M	0.0	0.0	0.0	0.0
Capital Lease Obligations	4.1M	6.8M	7.1M	8.2M	8.8M	9.5M	10.1M	0.0	0.0	34K	68K	101K	135K
Total Liabilities	1.4B	1.4B	947.9M	979.3M	489.1M	457.8M	218.9M	199.7M	31.5M	27.1M	12.6M	17.3M	3.5M
SHAREHOLDERS' EQUITY
Treasury Stock	-222.5M	-197.5M	-137.4M	-61.9M	-42.9M	0.0	0.0	0.0	0.0	0.0	-3K	-3K	-3K
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	97.7M	77.1M	73.8M
Common Stock	41K	40K	38K	37K	36K	35K	34K	33K	33K	29K	21K	8K	1K
Additional Paid-In Capital	625M	590.3M	565.9M	538.1M	502.1M	519.1M	447.3M	428.7M	402.1M	358.1M	214.1M	12.4M	12.3M
Retained Earnings	-101.1M	-164M	-233.2M	-281.3M	-256.3M	-333.1M	-359.9M	-337.2M	-298M	-223.2M	-129M	-101.8M	-80.5M
Accumulated Other Comprehensive Income/Loss	319K	55K	14K	0.0	0.0	0.0	0.0	0.0	-1.7M	-1.3M	-1.1M	-903K	-716K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8M	0.0
Total Stockholders' Equity	301.7M	228.8M	195.4M	194.8M	202.9M	186M	87.4M	91.6M	104.1M	134.9M	85.1M	-12.2M	5.6M
Total Equity	301.7M	228.8M	195.4M	194.8M	202.9M	186M	87.4M	91.6M	104.1M	134.9M	85.1M	-12.2M	5.6M
SUMMARY
Total Liabilities & Equity	1.7B	1.7B	1.1B	1.2B	692.1M	643.8M	306.3M	291.2M	135.6M	162M	97.7M	5.1M	9M
Total Investments	156.5M	92.2M	71.6M	0.0	0.0	0.0	0.0	0.0	97K	97K	97K	0.0	0.0
Total Debt	940.6M	859.3M	674.3M	709.2M	258.8M	266.6M	21.6M	11.5M	1.5M	4.1M	6.8M	13M	973K
Net Debt	689.5M	788.7M	435.3M	535.5M	72.3M	92.5M	-148.4M	-135.1M	-117.2M	-149.1M	-88.9M	11.4M	-6.6M
Shares Outstanding	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976	31,610,976

SEC Filings

COLL - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 15, 2026	May 14, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 07, 2026	May 14, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 07, 2026	April 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 19, 2026	March 19, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 08, 2026	2026	View Filing

Showing 1 to 10 of 186 filings

Related Guides

Blog Categories

Continue your COLL research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.